Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | -0.03 | 0.04 |
| FCF Yield | 38.59% | -14.78% | -5.72% | -12.50% |
| EV / EBITDA | -2.81 | -3.09 | -5.32 | -2.92 |
| Quality | ||||
| ROIC | -25.05% | -162.93% | -794.82% | -940.58% |
| Gross Margin | 67.62% | 77.37% | 0.00% | 0.00% |
| Cash Conversion Ratio | -3.07 | 0.11 | 0.15 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 151.11% | -414.91% | -112.26% | 60.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.23 | 0.10 | 0.00 |
| Interest Coverage | -80.16 | -4.01 | -2,091.91 | -77.23 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.06 | 0.00 | 0.00 |
| Cash Conversion Cycle | 310.19 | -37,211.88 | 0.00 | 0.00 |